Afya stock surges as direct US listing for Brazil medical giant shines

Brazilian medical education giant Afya Limited saw its Nasdaq-listed shares surge 7.46% on Monday, closing at $13.13. The rally highlights a unique corporate structure: Afya is one of the very few Brazilian companies that international retail investors can buy directly on a US exchange without going through an American Depositary Receipt (ADR). Headquartered in Belo Horizonte, Minas Gerais, Afya operates a massive network of medical schools and digital health solutions across Brazil.

The sudden market enthusiasm comes on the heels of a massive consolidation wave in Brazil's higher education sector. On September 23, 2026, Afya signed a binding agreement to merge with Yduqs Participações S.A., another major Brazilian education group. Under the terms of the deal, the two companies will combine to serve approximately 1.6 million students, including 38,000 medical students, creating a powerhouse with an estimated annual net revenue of R$9.4 billion ($1.88 billion).

For foreign investors, however, this transaction comes with a ticking clock. Because the combined entity will be absorbed under Yduqs and listed exclusively on Brazil's B3 exchange in São Paulo, Afya's direct Nasdaq listing is scheduled to be delisted once the transaction is finalized. The companies have set a long stop date of March 31, 2028, to complete the regulatory approvals, which include antitrust clearance from Brazil’s Administrative Council for Economic Defense (CADE).

Navigating the regulatory path

The merger represents a major shift in how foreign capital accesses Brazil’s highly profitable private healthcare education market. Until the deal closes, investors are treating the Nasdaq-listed shares as a direct arbitrage play on the future combined company, where Afya shareholders are slated to own 69% of the new entity. German media conglomerate Bertelsmann, which currently controls Afya, will emerge as the largest single shareholder of the combined group with a 47.4% stake.

While the operational synergies of combining 176 campuses across Brazil are clear, the transaction must still clear significant regulatory hurdles. CADE, Brazil's antitrust watchdog, is known for its rigorous review of market concentration in regional education hubs. To mitigate risks, the companies have established a voting commitment agreement among major shareholders and agreed to hefty break-up fees of up to R$650 million if the transaction falls through after shareholder approval.

What it touches

The immediate impact of this movement is concentrated in the education and consumer services sectors. Investors trading Afya directly on the Nasdaq (AFYA) or tracking Yduqs on the B3 (YDUQ3) are exposed to the progress of the regulatory approvals and the eventual transition of all equity to the Brazilian exchange. This transition will eventually require foreign retail investors to access the stock through local brokers or international depositary channels once the Nasdaq vehicle ceases to exist.